Cardiac Webinar Recording

The use of NT-proBNP in hospital and ambulatory settings: Translating the evidence to clinical practice

View Recording

What you will learn

The APAC Experts Consensus’ recommendation on the prognostic thresholds of NT-proBNP to determine which patients are at increased risk of poor outcomes in different clinical setting
How to incorporate NT-proBNP prognostic information in clinical decision for better management of HF patients

Speaker

James L. Januzzi

MD
Hutter Family Professor of Medicine at Harvard Medical School, Staff Cardiologist at Massachusetts General Hospital, and Senior Cardiometabolic Faculty at Baim Institute for Clinical Research

Read More

Speaker

Yi-Heng Li

MD, PhD, FACC, FESC
Senior Attending Physician of the Division of Cardiology and Professor at Department of Internal Medicine in the College of Medicine at National Cheng Kung University Hospital in Tainan, Taiwan

Read More

Moderator

Naoki Sato

MD, PhD, is Director of Cardiovascular Medicine, General Manager of Internal Medicine, and vice-president of Kawaguchi Cardiovascular and Respiratory Hospital, Japan.
 

Read More

Q&As

  • Because of the smaller LV chamber size in HFpEF, the wall tension is lower in such patients and therefore NT-proBNP is often lower. Sometimes it may be below the threshold for acute heart failure, but please keep in mind that "normal" NT-proBNP for an adult is <100 pg/mL, so most patients with HFpEF don't have a "normal" value, but it might not be as high as HFrEF.
  • NT-proBNP remains prognostic in HFpEF, so following concentrations is advised
NT-proBNP may be useful in pediatric applications. After about 1 year of age, the cut-offs remain the same as in adults--for acute HF, <450>
NT-proBNP may be useful in pediatric applications. After about 1 year of age, the cut-offs remain the same as in adults--for acute HF, <450>
There is not cut-off to indicate use of ARNI. ARNI should be prescribed in patients with symptomatic HFrEF.
Answer by Pr Li
No matter what drugs used for heart failure treatment, NT-proBNP should be measured at baseline and after a period of treatment. If patients are stable, I prefer to follow up NT-proBNP every 3 to 6 months.
You can do that for asymptomatic subjects. Actually, there were studies using NT-proBNP to screen the presence of left ventricular dysfunction in general population.
Yes. Some studies reported that exercise training could reduce NT-proBNP level in chronic heart failure patients

Coming Soon

Cardiac Biomarker Webinar

The novel biomarker-based risk score in Atrial Fibrillation: GDF-15 and ABC risk score

Date and Time: Friday, 4 October 2019 | 15:00 - 16:00 (GMT+08:00)

Moderator & Speaker

Adj Assoc Prof Ching Chi Keong

Adj Assoc Prof Ching is a Senior Consultant with the Department of Cardiology and the Director of Cardiac Electrophysiology and Pacing at the National Heart Centre Singapore.

Moderator

Prof Lars Wallentin

Prof Wallentin is a Senior Professor of Cardiology and founder of the Uppsala Clinical Research Centre (UCR) at Uppsala University Hospital, Uppsala, Sweden.

To learn more information or join the Cardiac Biomarker webinar, pleaseMore visit this webpage.